Funding for this research was provided by:
Janssen Research and Development
Received: 6 August 2019
Accepted: 10 March 2020
First Online: 11 May 2020
Ethics approval and consent to participate
: Institutional Review Boards approved the study protocol and its amendments. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, consistent with Good Clinical Practices and applicable regulatory requirements. Participants, their parents (for participants < 18 years old), or legally authorized representatives provided written informed consent before participating in the study.
: Not applicable.
: AB, JM, MC, SN, MB, NVM, and GP are employees of Janssen Research & Development, LLC, and may hold company equity. AS was an employee of Janssen Research & Development at the time of the study. MSG has received research and consulting funding from Janssen Research & Development. GD is on the Scientific Advisory Boards of Janssen Research & Development; Akili, Inc.; LabCorp, Inc.; and Roche Pharmaceutical Company; is a consultant for Apple, Inc; Gerson Lehrman Group; Guidepoint, Inc.; and Axial Ventures; has received grant funding from Janssen Research & Development; and is the CEO of DASIO, LLC. GD receives royalties from Guilford Press, Springer, and Oxford University Press. RH received reimbursement for consultation from Janssen Research & Development. BL has received research grant funding from the NIH; is a consultant to Janssen Research & Development, the Illinois Children’s Healthcare Foundation; and is a board member of the Brain Research Foundation. FS is on the Scientific Advisory Board, is a consultant to and received grant funding from Janssen Research & Development, and has also received grant funding from Roche.